Source:http://linkedlifedata.com/resource/pubmed/id/19609243
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2009-7-17
|
| pubmed:abstractText |
No curative treatment is currently available for refractory or relapsed Hodgkin lymphoma (HL) after high-dose chemotherapy. Thus, new drugs with different modes of action are needed. Vascular endothelial growth factor (VEGF), a key regulator of tumor-angiogenesis, is elevated in sera of patients with HL. Hodgkin and Reed-Sternberg cells also express the growth-stimulating VEGF-R2 receptor suggesting that VEGF could contribute to the pathophysiology of this malignancy. We investigated the effects of the humanized anti-VEGF monoclonal antibody bevacizumab (BV) against human HL xenografts in severe combined immune deficiency mice and in a compassionate use program in HL patients with multiple relapsed and progressive diseases. After a 4-week run-in phase of single agent BV, combined gemcitabine and BV therapy was administered. In the animal model, BV delayed the growth of HL tumors significantly (P=0.0004). Out of 5 patients included, BV alone had biologic effects as determined by tumor size, blood flow, fluorodeoxyglucose-uptake, and serum markers CCL17/thymus and activation-related chemokine, and sCD30 in 4 patients. The combination of BV and gemcitabine led to partial or complete remission in 3 of 5 patients. Accordingly, VEGF deprivation by the anti-VEGF antibody BV has antitumor activity in established HL tumors in a preclinical model. Furthermore, BV single agent therapy has biologic effects in HL patients indicating clinical activity. On the basis of these results, a prospective clinical study has been initiated to further investigate the impact of this antiangiogenic approach in HL.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Angiogenesis Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine,
http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A,
http://linkedlifedata.com/resource/pubmed/chemical/bevacizumab,
http://linkedlifedata.com/resource/pubmed/chemical/gemcitabine
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1537-4513
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
32
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
508-12
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:19609243-Adult,
pubmed-meshheading:19609243-Angiogenesis Inhibitors,
pubmed-meshheading:19609243-Animals,
pubmed-meshheading:19609243-Antibodies, Monoclonal,
pubmed-meshheading:19609243-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:19609243-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19609243-Cell Growth Processes,
pubmed-meshheading:19609243-Deoxycytidine,
pubmed-meshheading:19609243-Disease Models, Animal,
pubmed-meshheading:19609243-Drug Resistance, Neoplasm,
pubmed-meshheading:19609243-Female,
pubmed-meshheading:19609243-Hodgkin Disease,
pubmed-meshheading:19609243-Humans,
pubmed-meshheading:19609243-Immunotherapy,
pubmed-meshheading:19609243-Male,
pubmed-meshheading:19609243-Mice,
pubmed-meshheading:19609243-Mice, SCID,
pubmed-meshheading:19609243-Neoplasm Transplantation,
pubmed-meshheading:19609243-Tumor Burden,
pubmed-meshheading:19609243-Vascular Endothelial Growth Factor A
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.
|
| pubmed:affiliation |
Laboratory of Immunotherapy, Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany.
|
| pubmed:publicationType |
Journal Article
|